NASDAQHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading OPRX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity with a focus on the healthcare sector. The current thesis state is intact, supported by strong recent financial performance, but management execution has been volatile.
The market appears to price OPRX as relatively cheap compared to its peers, with a significant expectations gap. Currently, there is low fragility in the stock's valuation, suggesting that the market does not anticipate major disruptions.
Fundamentals may show mixed results as management aims to achieve revenue and adjusted EBITDA guidance for 2026. However, cash flow from operations has deteriorated, indicating challenges ahead.
The long-term thesis hinges on management's ability to meet revenue and EBITDA targets, as well as the performance of sector bellwethers like VEEV, BTSG, and TEM. Any cuts in guidance or negative earnings from these companies could impact OPRX's trajectory.
Overall, OPRX's performance will depend on management's execution and sector trends over the next few years. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This report will show if the company is on track to meet its $109M-$114M revenue goal for 2026.
Confirms:Q2 revenue was below $25 million. This shows a big gap from the target.
Disproves:Q2 revenue is over $30 million. This shows better performance towards the revenue goal.
Why it matters: The company aims for $95-$100 million in revenue for 2026. Confirmation shows progress.
Confirms:Q2 revenue guidance is confirmed or raised above $100 million.
Disproves:Q2 revenue guidance is lowered below $95 million.
Why it matters: Improving cash flow is crucial for the company's financial health and future growth.
Confirms:Cash from operations is positive. This shows recovery from the negative $467,000 in Q1.
Disproves:Cash from operations is still negative or gets worse. This shows ongoing financial strain.
Why it matters: Adjusted EBITDA shows how profitable a company is. Meeting guidance means the company is doing well.
Confirms:Adjusted EBITDA reported within the range of $21M-$25M.
Disproves:Adjusted EBITDA falls below $20M.
Why it matters: This shows if the company is getting closer to its EBITDA goal of $21M-$25M for 2026.
Confirms:Adjusted EBITDA was below $5 million. This shows no progress has been made.
Disproves:Adjusted EBITDA is more than $10 million. This is better than expected.
Why it matters: Improving cash from operations is key for the company's financial health and growth.
Confirms:Cash from operating activities is getting better. It goes up every quarter.
Disproves:Cash from operating activities is going down or staying the same. This shows problems.
Why it matters: The new CCO's plan may greatly affect sales and revenue after the recent change.
Confirms one read:Announcement of a clear, positive strategy from the new CCO.
Confirms the other:No clear strategy or negative news from the new CCO.
Why it matters: The company aims for adjusted EBITDA of $21-$25 million in 2026. This shows strong operations.
Confirms:Adjusted EBITDA for Q2 is over $6 million.
Disproves:Adjusted EBITDA for Q2 falls below $5 million.
